Patents by Inventor James Andya

James Andya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein formulation
    Publication number: 20060275306
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: May 26, 2006
    Publication date: December 7, 2006
    Inventors: James Andya, Jeffrey Cleland, Chung Hsu, Xanthe Lam, David Overcashier, Steven Shire, Janet Yang, Sylvia Wu
  • Protein formulation
    Patent number: 7060268
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: June 13, 2006
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Treating a mammal with a formulation comprising an antibody which binds IgE
    Publication number: 20060099201
    Abstract: A method of treating a mammal with a formulation comprising an antibody which binds IgE as described.
    Type: Application
    Filed: December 16, 2005
    Publication date: May 11, 2006
    Applicant: Genentech, Inc.
    Inventors: James Andya, Chung Hsu, Steven Shire, Sylvia Wu
  • Antibody formulations
    Publication number: 20060088523
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: October 19, 2005
    Publication date: April 27, 2006
    Inventors: James Andya, Shiang Gwee, Jun Liu, Ye Shen
  • Protein formulation
    Patent number: 6685940
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: March 14, 2001
    Date of Patent: February 3, 2004
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Protein formulation
    Publication number: 20030202972
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: May 2, 2003
    Publication date: October 30, 2003
    Applicant: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Protein formulation
    Publication number: 20010014326
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: March 14, 2001
    Publication date: August 16, 2001
    Applicant: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Protein formulation
    Patent number: 6267958
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: March 14, 1996
    Date of Patent: July 31, 2001
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu